AOD-9604 research — Private Peptides
The fat-metabolism experiment that reached human trials and missed its weight-loss endpoint.
The human weight-loss result
AOD-9604 research also appears under the spellings AOD9604 and AOD 9604. The compound is a synthetic 16-amino-acid fragment based on the fat-metabolism region of human growth hormone. Its obesity development program ended around 2007 after the pivotal human trial failed to demonstrate statistically significant weight loss versus placebo.
The clinical record seemed the fairest place to test my sympathy for the mechanism, so the 2013 human safety and tolerability paper came first. Across roughly six trials in about 900 obese adults, tolerability resembled placebo. That is a useful finding. The failed weight-loss endpoint still settles the question the obesity program was built to answer.
Opinion on its fat-loss reputation: the human result deserves the opening paragraph. Resurrecting the mouse results as though the trials never happened gives this molecule an easier history than it earned.
The title of the human paper names safety and tolerability. Its reassuring result has a specific job.
The growth-hormone fragment
The starting idea was economical: retain a piece of growth hormone associated with fat metabolism and leave its growth-promoting activity behind. AOD-9604 was modeled on residues 177-191 with an N-terminal tyrosine substitution; its structure includes a disulfide bridge, a bond joining the cysteine residues within the peptide.
The 1983 work on a C-terminal growth-hormone sequence examined adipocyte and hepatocyte preparations in vitro. It showed inhibition of acetyl-CoA carboxylase, an enzyme involved in making new fatty acids. That gives the old term antilipogenic a concrete meaning: less new fat synthesis. Later metabolic studies of AOD9604 developed the fragment’s fat-metabolism story in laboratory and rodent systems.
I’m sympathetic to that design ambition. A narrowly chosen fragment is an appealing experiment, even when the eventual clinical answer is disappointing.
Beta3-AR knockout mice
The 2001 obese-mouse and beta3-AR knockout experiment gives the animal story a useful complication. After 14 days of chronic treatment, weight and fat fell in obese mice and beta-3 adrenergic receptor expression increased. In mice lacking that receptor, the chronic weight and fat response disappeared. Acute increases in energy expenditure and fat oxidation persisted.
Another obese-mouse study reported increased fat oxidation and weight loss with the modified fragment. Both papers concern mice. I like the knockout experiment because the missing receptor forces a sharper question: different measured effects can depend on different pathways. A broad fat-burning description loses that distinction, and the human obesity program supplied no demonstrated weight-loss benefit to rescue it.
Exposure and tolerability
The human safety report covers trial durations from 7 days to 24 weeks. Its placebo-like tolerability result leaves rare and longer-term human risks poorly characterized. In the non-clinical safety and metabolism evaluation, rat and primate studies raised no genotoxic or toxicological concern, and a pig intravenous pharmacokinetic model showed a half-life of about three minutes. Animal clearance figures cannot establish a human injection interval.
AOD-9604 has no regulatory approval for any indication. FDA’s page current as of April 22, 2026 records its compounding nomination as withdrawn, with safety concerns retained; that entry establishes no permission to compound. As a growth-hormone fragment it is prohibited at all times in sport under WADA Section S2. These are the regulatory positions recorded on this site, separate from the tolerability finding.
The cartilage detour
The rabbit knee osteoarthritis experiment investigated a different question altogether. In 32 New Zealand white rabbits with collagenase-induced osteoarthritis, intra-articular AOD9604, with or without hyaluronic acid, reduced cartilage-degeneration scores versus saline over 4-7 weeks.
That is a preclinical joint result. Human osteoarthritis efficacy remains unestablished. I’d give the cartilage question its own hearing; borrowing it to refresh the abandoned obesity pitch muddles two separate projects.
Community accounts
The community accounts collected for AOD-9604 are anecdotal and carry no clinical evidentiary weight. People describe easy tolerability, little noticeable fat loss, occasional local redness or itching, and disappointment compared with the claims surrounding the molecule. Where visible change is described, diet and training often changed at the same time.
Localized fat-loss stories also circulate. The human trial record supplies no support for that claim. I distrust that escape from the failed endpoint; neither the contents of research-labelled material nor the source of a reported change is established by the story.
Compare the endpoints across these compounds, including the very different human records for MOTS-c and retatrutide.